Should You Buy SpaceX After Its IPO? Here Are 3 Lessons to Heed from Warren Buffett

The article argues SpaceX's IPO valuation is stretched, citing a $2.1 trillion market cap, 2025 revenue of $18.7 billion, and a price-to-sales ratio above 112. Morningstar's probability-weighted DCF values the stock at $63 per share, about 42% of the IPO price, and labels it significantly overvalued. It also highlights governance risk from Elon Musk's 82.4% voting power and complexity from the xAI merger and possible future Tesla involvement.

Analysis

The first-order read is not about a single stock; it is about how public-market capital tends to monetize optionality before the operating model is fully proven. That setup usually transfers the best part of the risk/reward from insiders to new holders, and the governance angle matters as much as valuation when control remains highly concentrated. In practice, that means any mismatch between narrative momentum and cash-flow visibility can persist for quarters, but it eventually widens the gap between what the equity trades on and what the business can actually compound.

The most interesting second-order effect is on adjacent AI and space-exposure trades. If investors are forced to mark up a highly speculative “AI + infrastructure + launch” story, capital may rotate into cleaner beneficiaries with more legible economics—particularly compute picks-and-shovels and networked software names with stronger gross-margin durability. That is modestly supportive for NVDA on sentiment, but only as a relative beneficiary; the better trade is likely in the ecosystem suppliers that do not require underwriting a moonshot terminal scenario to justify upside.

For MORN, the article creates a subtle problem: once a widely read valuation house is seen as “calling the top” on a headline IPO, its own brand can be pressured at the margin if the market continues to disregard its estimate. That is not a near-term earnings issue, but it can affect perceived relevance of its research franchise in hot-mania markets. TSLA is the cleaner second-order short exposure because any future tie-up speculation raises execution complexity and valuation dispersion, even if it does not change fundamentals immediately.

The contrarian point is that extreme pricing can stay extreme longer than skeptics expect if the asset becomes a benchmark for AI optionality rather than a conventional industrial or aerospace name. The key catalyst that would invalidate the bearish view is not hype—it is proof of monetization in enterprise AI with accelerating margin conversion over the next 2-4 quarters. Until then, the skew favors waiting for post-IPO supply to clear and for the market to demand audited, recurring economics rather than narrative expansion.

Key Decisions for Investors

• Avoid initiating a fresh long in the new IPO exposure for now; wait 4-8 weeks for lockup/supply overhang to clear and for the first post-deal trading range to form. Risk/reward is poor while price discovery is still narrative-driven.
• Pair trade: long NVDA / short the most expensive AI-optionality basket implied by the story, using a 3-6 month horizon. If the market rotates toward durable AI cash flows, NVDA should outperform without needing a step-function change in sentiment.
• Consider a tactical short in TSLA into any further crossover-merger speculation headlines, sized small and hedged. The thesis is not collapse, but multiple compression from complexity and governance overhang over the next 1-3 months.
• For MORN, treat any weakness as a potential overreaction only if valuation commentary becomes a recurring narrative. Otherwise stay neutral; this is a reputational, not fundamental, risk over a 6-12 month horizon.
• If you want optionality on a blow-off move, use small call spreads rather than stock in the IPO name. That caps downside while preserving upside if the market keeps paying for the moonshot scenario over the next quarter.